Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biocept Inc (NQ: BIOC )

5.120 USD +0.260 (+5.35%)
Official Closing Price Updated: 5:23 PM EST, Dec 3, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biocept Inc

< Previous 1 2 3 4 5 6 Next >
While The U.S. Faces Insufficient COVID-19 Testing Volume, EIR Healthcare Launches MedModLabs to Expand Access Immediately
Healthcare design innovation firm known for its 'hospital in a box' solution expands modular offerings with new MedModLabs initiative, first rolling out in Philadelphia to help address Pennsylvania's... 
From PR Newswire
Study Shows Biocept's Assays are Viable and Sensitive for Detecting Tumor Cells and Biomarkers in the Cerebrospinal Fluid of Patients with Breast and Lung Cancer that has Metastasized to the Central N
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve... 
From PR Newswire
Results from Study Using Biocept's Target Selector™ Testing to Monitor Breast Cancer Disease Progression to be Presented at 2020 SABCS®
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve... 
From PR Newswire
Biocept Reports Third Quarter 2020 Financial Results
Revenues of $6.6 million - a result of decision to offer COVID-19 testing 
From PR Newswire
Thinking about buying stock in IMAC Holdings, Advanced Micro Devices, Biocept, Li Auto, or EuroDry?
InvestorsObserver issues critical PriceWatch Alerts for IMAC, AMD, BIOC, LI, and EDRY. 
From PR Newswire
Biocept Provides Update on COVID-19 Testing with More than 100,000 Samples Received
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with... 
From PR Newswire
Biocept Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, including Cancer Cells
Further expands global patent estate for capturing and detecting rare cells of interest, including CTCs, to aid in the treatment of patients with cancer 
From PR Newswire
Biocept Awarded Broad Japanese Patent for the Use of Binding Entities in Combination with any Solid Surface to Capture and Detect any Target of Interest, including CTCs, from any Sample Type
Biocept further expands its patent estate for capturing and detecting target cells of interest, including CTCs 
From PR Newswire
Biocept to Release Third Quarter 2020 Financial Results and Host Investor Conference Call on November 12, 2020
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces that it will release financial results for the... 
From PR Newswire
Biocept Provides Update on COVID-19 Testing with More than 80,000 Samples Received
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces an update on its COVID-19 testing with... 
From PR Newswire
Biocept Appoints Samuel D. Riccitelli to its Board of Directors
Diagnostic industry veteran plans immediate start 
From PR Newswire
Biocept Provides Update on COVID-19 Testing with More than 50,000 Specimens Received
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces it has received more than 50,000 COVID-19... 
From PR Newswire
Study Shows Biocept's Target Selector™ May Provide a More Robust Method for Detecting Lung Cancer Metastasis in Cerebrospinal Fluid than Cytology
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients, announces results from a prospective study comparing its... 
From PR Newswire
Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy Meeting
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve... 
From PR Newswire
Biocept Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations in Tissue, Blood and Cerebrospinal Fluid
Further expands Company's patent portfolio in pursuit of worldwide intellectual property protection for Primer-Switch technology for the field of oncology 
From PR Newswire
Aegea Biotechnologies, Inc. Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Genetic Alterations and Variants
Further expands Company's patent portfolio in pursuit of worldwide intellectual property protection for Primer-Switch technology; Applicable to Coronavirus (COVID-19) Molecular Diagnostic Testing 
From PR Newswire
Thinking about buying stock in Avadel Pharmaceuticals, Nikola Corp, Agile Therapeutics, Biocept Inc, or Uber Technologies?
InvestorsObserver issues critical PriceWatch Alerts for AVDL, NKLA, AGRX, BIOC, and UBER. 
From PR Newswire
Biocept Announces that Highmark Has Made a Positive Coverage Determination on Target Selector™ Liquid Biopsy
Two-year evaluation in advanced lung cancers at Allegheny Health Network demonstrated improved access to optimal treatment while reducing healthcare costs 
From PR Newswire
Thinking about buying stock in Pacific Ethanol, Inovio Pharmaceuticals, Scientific Games, Biocept, or Delta Air Lines?
InvestorsObserver issues critical PriceWatch Alerts for PEIX, INO, SGMS, BIOC, and DAL. 
From PR Newswire
Biocept Provides COVID-19 Testing Update with More than 35,000 Specimens Received
Announces distribution of approximately 83,000 specimen collection kits to clients 
From PR Newswire
Aegea Biotechnologies, Inc. Advances to Semi-Finals of the $5M XPRIZE Rapid COVID Testing Competition
Aegea Biotechnologies' New, Highly Sensitive PCR-based COVID-19 Assay Utilizing Patented Switch-Blocker Technology Advances in the Global XPRIZE Competition Seeking "Faster, Cheaper, and Easier-to-Use... 
From PR Newswire
Biocept to Present at the H.C. Wainwright Global Investment Virtual Conference on September 14
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular diagnostics designed to provide physicians with clinically actionable information to improve the patient outcomes, announces... 
From PR Newswire
Biocept Executes In-Network Provider Agreement with Health Net Federal Services Extending Coverage for its Liquid Biopsy Oncology Platform to the TRICARE West Region Network
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces it has... 
From PR Newswire
Biocept Announces One-for-Ten Reverse Stock Split
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces that,... 
From PR Newswire
Biocept Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More than 20,000 Specimens Processed
Announces distribution of approximately 46,000 specimen collection kits to clients 
From PR Newswire
Biocept to Present at the LD Micro 500 Virtual Conference
Biocept, Inc. (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients, announces... 
From PR Newswire
Biocept Names Michael Dugan, M.D. Chief Medical Officer and Medical Director
From GlobeNewswire News Releases
Biocept to Present at the Proactive One2One Virtual Investor Forum on August 25
From GlobeNewswire News Releases
Biocept Expands Agreement with MultiPlan to Include COVID-19 Testing
From GlobeNewswire News Releases
Aegea Biotechnologies, Inc. Announces the Issuance of U.S. Patent for Primer-Switch Nucleic Acid Probes for the Detection of Rare Genetic Events and for PCR Amplification Improvements
Expands Aegea Biotechnologies' Intellectual Property for Methods of Detecting Rare Genetic Events and for Methods to Improve PCR Amplification Reactions; Applicable to Coronavirus (COVID-19) Molecular... 
From PR Newswire
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.